All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-1022-LX643 | Anti-FAP (X10X475) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X475 | Mouse | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX644 | Anti-FAP (X10X476) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X476 | Mouse | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1297 | Anti-FAP (X10X475) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X475 | Mouse | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1298 | Anti-FAP (X10X476) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X476 | Mouse | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1951 | Anti-FAP (X10X475) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X475 | Mouse | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1952 | Anti-FAP (X10X476) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X476 | Mouse | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1122-YF390 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-390), pCDCAR1 | Human | XW-390 | Human | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF391 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-391), pCDCAR1 | Human | XW-391 | Human | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF392 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-392), pCDCAR1 | Human | XW-392 | Human | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF393 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-393), pCDCAR1 | Mouse | XW-393 | Human | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF394 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-394), pCDCAR1 | Mouse | XW-394 | Human | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF395 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-395), pCDCAR1 | Mouse | XW-395 | Human | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF396 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-396), pCDCAR1 | Human | XW-396 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF397 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, MO36), pCDCAR1 | Human; Mouse | MO36 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF398 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-398), pCDCAR1 | Human | XW-398 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF399 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-399), pCDCAR1 | Human; Mouse | XW-399 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF400 | Anti-FAP KIR CAR (scFv-KIR2DS2-DAP12, XW-400), pCDCAR1 | Human; Mouse | XW-400 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF1310 | Anti-FAP TCR-ABR (scFv-TCRα, XW-390) CAR Plasmid, pCDCAR1 | Human | XW-390 | Human | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-1122-YF1311 | Anti-FAP TCR-ABR (scFv-TCRα, XW-391) CAR Plasmid, pCDCAR1 | Human | XW-391 | Human | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-1122-YF1312 | Anti-FAP TCR-ABR (scFv-TCRα, XW-392) CAR Plasmid, pCDCAR1 | Human | XW-392 | Human | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-0823-LX44 | Anti-hFAP (36) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | 36 | Adenoviral vectors |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION